JPRN-UMIN000006730已完成未知
Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer. - HSP105 peptide-pulsed dendritic cell vaccination therapy for advanced/ recurrent cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; 2) Serious drug allergy; 3) Difficult infections to control; 4) Serious cardiac disease; 5) Active autoimmune diseases; 6) Other cancers; 7) Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
研究者
相似试验
已完成
1 期
Phase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/ colo- rectal cancer.advanced esophageal cancer/ colo- rectal cancerJPRN-UMIN000017809ational Cancer Center Hospital East15
招募中
不适用
Signal transduction of heat shock protein in hepatitis and hepatocellular carcinomahepatitis and hepatocellular carcinomaJPRN-UMIN000003462Department of Pharmacology, Gifu University Graduate School of Medicine300
Unknown
不适用
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor CellsMelanoma Stage IVSarcomaPancreatic Cancer Stage IVBreast Cancer Stage IVProstate CancerSquamous Cell CarcinomaNCT04628806Charite University, Berlin, Germany120
终止
1 期
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) VaccineAstrocytoma, Grade IIIAnaplastic EpendymomaClear Cell EpendymomaEpendymomaGlioblastoma MultiformeNCT02722512Ann & Robert H Lurie Children's Hospital of Chicago10
已完成
不适用
Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS)Myeloproliferative SyndromeNCT02873832Centre Hospitalier Universitaire Dijon37